Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Teucrium Wheat Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Teucrium Wheat Fund trades at $24.38 (market cap $274.59M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 17.8× Teucrium Wheat Fund's market cap, and Teucrium Wheat Fund is more actively traded (203,622 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Teucrium Wheat Fund for 42 Days on average.
| TVTX | WEAT | |
|---|---|---|
Market Cap | $4.88B | $274.59M |
Volume | 1,668,577 | 203,622 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $67.52 | $28.00 |
52-Week Low | $26.79 | $19.88 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
WEAT trades at $24.28, down 0.74% today, with a bearish technical signal from moving averages. Recent news highlights a 25% year-to-date gain as of July 2026, driven by wheat market dynamics, though inflation concerns persist. Key support is at $24, with resistance at $25. The absence of fundamental ratios like P/E and P/S in the data limits valuation clarity, but the ETF's performance is tied to agricultural commodity trends.
The outlook is cautious due to bearish technical indicators and macroeconomic inflation pressures. Opportunities exist if wheat prices rally, but risks include commodity volatility and Federal Reserve policy impacts. Investors should weigh the ETF's lack of traditional company fundamentals against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
